JP2022535609A5 - - Google Patents

Info

Publication number
JP2022535609A5
JP2022535609A5 JP2021573165A JP2021573165A JP2022535609A5 JP 2022535609 A5 JP2022535609 A5 JP 2022535609A5 JP 2021573165 A JP2021573165 A JP 2021573165A JP 2021573165 A JP2021573165 A JP 2021573165A JP 2022535609 A5 JP2022535609 A5 JP 2022535609A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
adc
alkyl
treatment
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535609A (ja
JP7740994B2 (ja
Filing date
Publication date
Priority claimed from GBGB1908234.6A external-priority patent/GB201908234D0/en
Priority claimed from GBGB1908233.8A external-priority patent/GB201908233D0/en
Application filed filed Critical
Priority claimed from PCT/EP2020/065880 external-priority patent/WO2020249528A1/en
Publication of JP2022535609A publication Critical patent/JP2022535609A/ja
Publication of JP2022535609A5 publication Critical patent/JP2022535609A5/ja
Application granted granted Critical
Publication of JP7740994B2 publication Critical patent/JP7740994B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573165A 2019-06-10 2020-06-08 抗ｃｄ１９抗体薬物複合体とｐｉ３ｋ阻害剤又は二次薬剤を含む併用治療 Active JP7740994B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1908234.6A GB201908234D0 (en) 2019-06-10 2019-06-10 Combination therapy
GBGB1908233.8A GB201908233D0 (en) 2019-06-10 2019-06-10 Combination therapy
GB1908233.8 2019-06-10
GB1908234.6 2019-06-10
PCT/EP2020/065880 WO2020249528A1 (en) 2019-06-10 2020-06-08 Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent

Publications (3)

Publication Number Publication Date
JP2022535609A JP2022535609A (ja) 2022-08-09
JP2022535609A5 true JP2022535609A5 (https=) 2023-06-13
JP7740994B2 JP7740994B2 (ja) 2025-09-17

Family

ID=71103360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573165A Active JP7740994B2 (ja) 2019-06-10 2020-06-08 抗ｃｄ１９抗体薬物複合体とｐｉ３ｋ阻害剤又は二次薬剤を含む併用治療

Country Status (11)

Country Link
US (1) US20220305132A1 (https=)
EP (1) EP3980079A1 (https=)
JP (1) JP7740994B2 (https=)
KR (1) KR20220020332A (https=)
CN (1) CN114302745A (https=)
AU (1) AU2020292965A1 (https=)
CA (1) CA3142645A1 (https=)
IL (1) IL288716B2 (https=)
MX (1) MX2021015403A (https=)
SG (1) SG11202113092WA (https=)
WO (1) WO2020249528A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240197783A1 (en) 2021-04-21 2024-06-20 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
EP4565217A1 (en) * 2022-08-04 2025-06-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
JP2025531798A (ja) * 2022-09-09 2025-09-25 上海▲瑛▼黎薬業有限公司 含窒素複素環化合物、その医薬組成物および使用
US12609718B2 (en) 2023-06-14 2026-04-21 Hewlett Packard Enterprise Development Lp WiFi-7 optimized split band architecture and method of operation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
BRPI0713119A2 (pt) * 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
RU2015141713A (ru) * 2010-03-25 2018-12-28 Эббви Инк. Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний
EP2550975A1 (en) * 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
JP6392765B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
HRP20182129T1 (hr) * 2012-10-12 2019-02-08 Adc Therapeutics Sa Konjugati protutijelo - pirolobenzodiazepin
MX338711B (es) * 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
HRP20190366T1 (hr) * 2012-10-12 2019-04-19 Medimmune Limited Pirolobenzodiazepini i njihovi konjugati
GB201317982D0 (en) * 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201506399D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201602356D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
GB201617466D0 (en) * 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3612839A1 (en) * 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy
CA3064804A1 (en) * 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
GB201806022D0 (en) * 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
ES3037206T3 (en) * 2018-08-31 2025-09-30 Adc Therapeutics Sa Combination therapy
WO2020109251A1 (en) * 2018-11-29 2020-06-04 Adc Therapeutics Sa Dosage regime
TWI729662B (zh) * 2019-01-04 2021-06-01 大陸商蘇州亞盛藥業有限公司 一種磺胺類化合物及製備磺胺類化合物的製程
JP2025507736A (ja) * 2022-02-28 2025-03-21 アーデーセー セラピューティクス ソシエテ アノニム 投薬レジメン

Similar Documents

Publication Publication Date Title
JP2022535609A5 (https=)
JP7190549B2 (ja) Ｈｄａｃ阻害剤とｐｄ－１阻害剤との組み合わせ療法
JP2019518741A5 (https=)
JP2022017295A5 (https=)
JP2019506403A5 (https=)
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
US20050244407A1 (en) Therapeutic synergy of anti-cancer compounds
JP2020505433A5 (https=)
JP2008530142A5 (https=)
JP2018524347A5 (https=)
FI4234581T3 (fi) Terapeuttisia vasta-aineita ja niiden käyttöjä
SI2809657T1 (en) New therapeutic agents
JP2012509889A5 (https=)
JP2011503063A5 (https=)
JP2018503610A5 (https=)
JP2021530444A5 (https=)
RU2019138222A (ru) Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли
WO2025061140A1 (zh) 治疗非霍奇金淋巴瘤的药物组合及其用途
JP2010534682A5 (https=)
JP2020523384A5 (https=)
JP2021535110A5 (https=)
JP2005514371A (ja) 抗ｔ細胞免疫毒素融合タンパク質およびその治療的使用
TW202102216A (zh) 抗腫瘤組合物
JP2021533090A5 (https=)
TW201834649A (zh) 癌症療法